コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 malaria and 10 to 16 hours in those with P. falciparum malaria).
2 or (cutaneous leishmaniasis), and Plasmodium falciparum (malaria).
3 ms that confer the lower susceptibility to P.falciparum malaria.
4 nt against confirmed or suspected Plasmodium falciparum malaria.
5 pecificity to microscopy in patients with P. falciparum malaria.
6 eans to interrupt transmission of Plasmodium falciparum malaria.
7 acious treatment of uncomplicated Plasmodium falciparum malaria.
8 1 with severe malaria) presenting with acute falciparum malaria.
9 s threat to the global control of Plasmodium falciparum malaria.
10 fectively treating drug-resistant Plasmodium falciparum malaria.
11 artile range, 0.78 to 1.07) in those with P. falciparum malaria.
12 or the treatment of uncomplicated Plasmodium falciparum malaria.
13 for gametocyte clearance and for safety in P falciparum malaria.
14 on of primaquine to limit transmission of P. falciparum malaria.
15 (DP), are recommended to treat uncomplicated falciparum malaria.
16 y period, none had an episode of clinical P. falciparum malaria.
17 accompanied by effective measures to prevent falciparum malaria.
18 unate in the treatment of adults with severe falciparum malaria.
19 iparum malaria and 15 with moderately severe falciparum malaria.
20 in adults with uncomplicated P. vivax or P. falciparum malaria.
21 een associated with protection from clinical falciparum malaria.
22 ontribute to the endothelial pathology of P. falciparum malaria.
23 n-blocking vaccines (TBV) against Plasmodium falciparum malaria.
24 and maintenance of antigenic diversity in P. falciparum malaria.
25 a component of a multivalent vaccine for P. falciparum malaria.
26 re central to the pathogenesis of Plasmodium falciparum malaria.
27 ts aged 6 months to 12 years with Plasmodium falciparum malaria.
28 that aim to control and ultimately eliminate falciparum malaria.
29 besity, is associated with severe Plasmodium falciparum malaria.
30 deployment in the control and eradication of falciparum malaria.
31 s the first-line treatment for uncomplicated falciparum malaria.
32 central pathophysiological process in severe falciparum malaria.
33 microscopically confirmed, uncomplicated P. falciparum malaria.
34 ine) in patients with acute uncomplicated P. falciparum malaria.
35 cacious in the treatment of uncomplicated P. falciparum malaria.
36 a key role in the pathogenesis of Plasmodium falciparum malaria.
37 in 14-3-3 protein epsilon in asymptomatic P. falciparum malaria.
38 standing the multifaceted epidemiology of P. falciparum malaria.
39 sensing via STING, TBK1 and IRF3-IRF7 in P. falciparum malaria.
40 ng in public health importance compared with falciparum malaria.
41 simulators cannot suitably model Plasmodium falciparum malaria.
42 ation therapy (ACT) for primary treatment of falciparum malaria.
43 egnancy (IPTp) is used to prevent Plasmodium falciparum malaria.
44 t of an effective vaccine against Plasmodium falciparum malaria.
45 lso confer some degree of resistance against falciparum malaria.
46 contributes to organ dysfunction and coma in falciparum malaria.
47 ng relevant to protection strategies against falciparum malaria.
48 ons affected the cytokine responses to acute falciparum malaria.
49 ties are associated with disease severity in falciparum malaria.
50 sults of PCR for the detection of Plasmodium falciparum malaria.
51 cts West African children against Plasmodium falciparum malaria.
52 tive liver-stage vaccines against Plasmodium falciparum malaria.
53 development of neurological complications of falciparum malaria.
54 infections protect against severe Plasmodium falciparum malaria.
55 nent of a vaccine against erythrocytic-stage falciparum malaria.
56 een inflammatory cytokines and disease in P. falciparum malaria.
57 he main cause of resistance to mefloquine in falciparum malaria.
58 ethamine (SP) as treatment for uncomplicated falciparum malaria.
59 nsidered for rescue treatment for Plasmodium falciparum malaria.
60 opoietin-2, and microvascular dysfunction in falciparum malaria.
61 oscopy or rapid test confirmed uncomplicated falciparum malaria.
62 umefantrine for treatment of uncomplicated P falciparum malaria.
63 T) is the first-line treatment of Plasmodium falciparum malaria.
64 e and transmission of multidrug-resistant P. falciparum malaria.
65 nsidered for rescue treatment for Plasmodium falciparum malaria.
66 is a strong predictor of mortality in severe falciparum malaria.
67 ll of whom required treatment for Plasmodium falciparum malaria.
68 eduction in deaths resulting from Plasmodium falciparum malaria.
69 ren from severe and uncomplicated Plasmodium falciparum malaria.
70 disease severity in Tanzanian children with falciparum malaria.
71 the modulating the pathogenesis of severe P falciparum malaria.
72 fication of antiadhesion drug candidates for falciparum malaria.
73 ariants protect African children from severe falciparum malaria.
74 elevated in 29 Indonesian adults with severe falciparum malaria (10%; 95% confidence interval [CI], 8
76 ction in 58 Gambian children with Plasmodium falciparum malaria [55 (95%) with uncomplicated disease]
77 bican children with uncomplicated Plasmodium falciparum malaria 7 days after combination treatment wi
78 ts aged 10 years or older with uncomplicated falciparum malaria, a density of asexual parasites of at
79 In keeping with findings in children with P falciparum malaria, acute endothelial cell activation wa
80 d complete return of chloroquine-susceptible falciparum malaria after chloroquine was withdrawn from
81 The evolution of resistance in Plasmodium falciparum malaria against most available treatments is
82 r border has led to a sustained reduction in falciparum malaria, although antimalarial efficacy has d
83 A total of 248 cases of severe Plasmodium falciparum malaria among children aged 3 months to 14 ye
85 study of 996 children with severe Plasmodium falciparum malaria and 1220 community controls and genot
86 oscopy in 13 Indonesian children with severe falciparum malaria and 15 with moderately severe falcipa
88 protection against infection with Plasmodium falciparum malaria and also against clinical malaria and
89 y lower proportionate morbidity ratios for P falciparum malaria and also for acute hepatitis and HIV/
90 ons from Vietnamese adults dying from severe falciparum malaria and compared the findings with the fi
91 were detected in the plasma of patients with falciparum malaria and correlated positively with diseas
94 ples from patients with confirmed Plasmodium falciparum malaria and in human whole-blood specimens st
95 he contemporary spatial limits of Plasmodium falciparum malaria and its endemicity within this range,
96 children aged 1-10 years with uncomplicated falciparum malaria and normal G6PD enzyme function to re
97 ate that neutrophil dysfunction occurs in P. falciparum malaria and support the relevance of the mech
98 vides new knowledge regarding immunity to P. falciparum malaria and underpins efforts to develop PfEM
100 ria, severe (n = 21) and nonsevere (n = 109) falciparum malaria, and healthy controls (n = 50), we me
101 hat iron deficiency anaemia protects against falciparum malaria, and that iron supplements increase s
102 vasion profile was associated with severe P. falciparum malaria, and there was no significant differe
109 as been critical for the globalization of P. falciparum malaria as parasites adapted to new vector sp
110 s a leading vaccine candidate for Plasmodium falciparum malaria, as antibodies against recombinant P.
112 relatively better protection from Plasmodium falciparum malaria, as reflected by fewer symptomatic ca
114 e enrolled boys and men with uncomplicated P falciparum malaria at the Malaria Research and Training
115 men in the second or third trimester who had falciparum malaria (at any parasite density and regardle
116 spatiotemporal prevalence of both Plasmodium falciparum malaria-attributable and non-malarial fever i
117 dering a change to combination treatment for falciparum malaria because of the increase in drug resis
119 urrent treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spreading acro
120 Artesunate is a vital therapy for Plasmodium falciparum malaria, but artesunate tablets have been cou
121 t recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance against them
122 ide (NO) bioavailability characterize severe falciparum malaria, but have not been assessed in severe
123 is known to be protective against Plasmodium falciparum malaria, but it is unclear when during the co
124 as introduced as treatment for uncomplicated falciparum malaria, but substantial resistance developed
125 eved to confer protection against Plasmodium falciparum malaria, but the precise nature of the protec
126 t efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortal
130 in 2010; examples were increased Plasmodium falciparum malaria (chi(2)=37.57, p<0.001); increased de
131 l known to protect against severe Plasmodium falciparum malaria, conclusive evidence on their role ag
136 as first-line agents to treat uncomplicated falciparum malaria due to their activity against multidr
138 malarials available, are not recommended for falciparum malaria during the first trimester of pregnan
140 HbS) - known to protect carriers from severe falciparum malaria - enhance parasite passage to mosquit
143 children aged 6-59 months with uncomplicated falciparum malaria from 3 health centers in 2013-2014 an
145 in vivo efficacy in a SCID mouse model of P. falciparum malaria, good oral bioavailability, favorable
147 The spread of drug-resistant Plasmodium falciparum malaria has been a major impediment to malari
148 ntroversy, the effect of ABO blood groups on falciparum malaria has been clarified, with the non-O bl
150 Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionall
153 ng host immunity in children with Plasmodium falciparum malaria has not previously been reported, cir
154 ations that confer artemisinin resistance in falciparum malaria have multiple independent origins acr
156 able to confer protection against Plasmodium falciparum malaria; however, a technology for formulatin
158 or mortality found in the rising rates of P. falciparum malaria importation to China can serve to ref
161 -80% reduced risk of clinical vivax, but not falciparum malaria in a prospective cohort study in the
162 arative analysis of treatment regimen for P. falciparum malaria in adults in Stockholm during 2000-20
163 been shown to be safe and effective against falciparum malaria in Africa and to have pronounced game
166 dults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in
169 apy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cambodia because of few remaining
173 studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (O
174 to the resistance it provides to Plasmodium falciparum malaria in its heterozygous state, called sic
175 reasing, creating a problem for diagnosis of falciparum malaria in locations without quality-assured
177 ded for the treatment of acute uncomplicated falciparum malaria in many malaria-endemic countries.
178 e hypothesized to protect against Plasmodium falciparum malaria in part by enhancing naturally-acquir
181 demic sub-Saharan Africa are attributed to P falciparum malaria in pregnancy; the population attribut
182 MAS3 in 1005 patients with uncomplicated P. falciparum malaria in relation to molecular markers of r
183 -line treatment for uncomplicated Plasmodium falciparum malaria in response to failing SP efficacy.
187 atients aged 2-65 years with uncomplicated P falciparum malaria in three Cambodian provinces: Pursat,
189 mergence of artemisinin-resistant Plasmodium falciparum malaria in western Cambodia could threaten pr
190 The burden of anemia attributable to non-falciparum malarias in regions with Plasmodium co-endemi
191 a transmission, susceptibility to Plasmodium falciparum malaria increases during first pregnancy.
192 evalence of artemisinin-resistant Plasmodium falciparum malaria increases in the Greater Mekong subre
193 s with four examples: identifying Plasmodium falciparum malaria-infected erythrocytes in a culture, d
194 a severe clinical complication of Plasmodium falciparum malaria infection and is characterized by a h
212 administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some setting
213 velopment of clinical immunity to Plasmodium falciparum malaria is thought to require years of parasi
216 world's most important vector of Plasmodium falciparum malaria, locate their human hosts primarily t
217 comparison, only 19 of 5076 patients with P. falciparum malaria (<1%) who were treated with oral arte
218 3 months to 14 years, with severe Plasmodium falciparum malaria matched to uncomplicated malaria or h
219 ese data show that hypoargininemia during P. falciparum malaria may altogether impair NO production a
220 plication during and after acute bouts of P. falciparum malaria may be due, at least in part, to ongo
221 sed combination therapy (ACT) for Plasmodium falciparum malaria may be threatened by parasites with r
222 ife-threatening diseases, such as Plasmodium falciparum malaria, melioidosis, and African trypanosomi
223 n with moderately severe (n = 77) and severe falciparum malaria (n = 129) had significantly higher mo
224 Patients aged >/=5 years with uncomplicated falciparum malaria, normal glucose-6-phosphate dehydroge
225 sma is a useful method for diagnosing severe falciparum malaria on fresh or archived plasma samples.
228 m 441 children presenting with uncomplicated falciparum malaria over 5 seasons (1998-2002) were linke
231 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 approximately 1 muM).
234 s unknown whether the presence of Plasmodium falciparum malaria parasites in umbilical cord blood den
236 erentiates Plasmodium falciparum from non-P. falciparum malaria parasites on the basis of the detecti
237 dent monoclonal antibodies raised against P. falciparum malaria parasites, it induced antibodies (Abs
239 ntigens play an important role in Plasmodium falciparum malaria pathogenesis and in immune evasion by
241 used therapeutically for treating Plasmodium falciparum malaria, Pneumocystis jirovecii pneumonia and
242 tively recruited children with uncomplicated falciparum malaria, pooling data from five African count
244 ht Bangladeshi and Indian adults with severe falciparum malaria received crystalloid resuscitation gu
254 r anti-disease therapy for severe Plasmodium falciparum malaria requires cellular and molecular defin
255 gan dysfunction and tissue hypoxia in severe falciparum malaria result from an imbalance between oxyg
257 t prognostic indicator in adults with severe falciparum malaria--results from sequestration of parasi
259 e assessed in 618 samples from patients with falciparum malaria studied prospectively over 12 years.
260 he molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence a
261 ia correlates with the development of severe falciparum malaria, suggesting that platelets either con
263 rker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-term clinical
264 hildren with severe anemia due to Plasmodium falciparum malaria; the results were similar to those in
265 ciency and severe and complicated Plasmodium falciparum malaria through a case-control study of 2220
266 lood group O may confer resistance to severe falciparum malaria through the mechanism of reduced rose
267 Emergence of CQ drug-resistant Plasmodium falciparum malaria throughout endemic areas of the world
268 ical model of the transmission of Plasmodium falciparum malaria to explore the potential effect on ca
270 safe and efficacious for the prevention of P falciparum malaria transmission in boys and men who are
271 has been seen with reductions in Plasmodium falciparum malaria transmission in some parts of Africa.
272 yzed with network analysis tools, Plasmodium falciparum malaria transmission maps, and global populat
274 a-regression analysis of cure rates from all falciparum malaria treatment trials (n = 40) with monoth
275 from British soldiers in Palestine, epidemic falciparum malaria triggered a smaller epidemic of P viv
276 gambiae mosquitoes that transmit Plasmodium falciparum malaria use a series of olfactory cues presen
277 mosquito, which is the vector for Plasmodium falciparum malaria, uses a series of olfactory cues eman
278 The development of an efficacious Plasmodium falciparum malaria vaccine remains a top priority for gl
280 ult patients (n = 28) with severe Plasmodium falciparum malaria were enrolled in a prospective hemody
281 g experimental challenge with mosquito-borne falciparum malaria were examined to identify markers ass
282 n Thailand, parasites from 101 patients with falciparum malaria were genotyped for antimalarial drug
283 ge, 6 months to 10 years) with uncomplicated falciparum malaria were randomized to artemether-lumefan
284 and (2009-2010), patients with uncomplicated falciparum malaria were randomized to oral artesunate 6
286 ear and a rapid diagnostic test positive for falciparum malaria were randomly assigned to groups that
289 tudies of genome-wide associations in severe falciparum malaria, which have identified the HBB locus
292 2 hours) in African children with Plasmodium falciparum malaria with a prespecified delta of 0.2.
293 ntrasts with the retinopathy of severe adult falciparum malaria with and without coma, suggesting tha
296 pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substan
297 nin-piperaquine treatment of uncomplicated P falciparum malaria, with and without the addition of pri
298 ce of climate on the incidence of Plasmodium falciparum malaria worldwide and how it might impact loc
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。